Molbio Diagnostics Swings to Profit in June 2026

A Major Financial Turnaround

Molbio Diagnostics has reported a significant shift in its financial performance for the quarter ended June 2026. The company successfully moved from a loss-making position in the previous year to recording a profit after tax of Rs 566.27 million.

This performance represents a sharp contrast to the June 2025 quarter, where the firm reported a total profit of Rs -134.05 million. The primary driver of this reversal appears to be a massive expansion in top-line revenue.

Revenue and Operational Efficiency

The company saw its total revenue climb to Rs 3993.78 million during the June 2026 quarter. This reflects a 318.99% increase compared to the Rs 953.20 million reported during the same period in the prior year.

Operational efficiency also saw a dramatic improvement during this timeframe. The following metrics highlight the company’s financial movement:

• Total Revenue: Rs 3993.78 million
• Profit After Tax: Rs 566.27 million
• PBIDT for the quarter: Rs 930.04 million
• Interest costs: Rs 86.62 million
• Depreciation charges: Rs 84.18 million

Contextualizing the Growth

The operating profit margin for the quarter ended June 2026 reached 930.04%, a substantial improvement from the -81.59% margin recorded in the corresponding quarter of 2025. While revenue surged by 318.99%, other income saw a slight decline of 7.69%, moving to Rs 13.68 million.

Interest expenses rose significantly to Rs 86.62 million, marking a 358.79% increase over the year-ago period. Depreciation also ticked upward by 13.54% to reach Rs 84.18 million.

The company’s ability to manage these rising costs while scaling revenue at a triple-digit pace defines the narrative for this reporting cycle. Future quarters will likely focus on whether this high level of operational profitability can be maintained as the scale of business operations continues to evolve.